A detailed history of Friedenthal Financial transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Friedenthal Financial holds 13,322 shares of HALO stock, worth $636,658. This represents 0.5% of its overall portfolio holdings.

Number of Shares
13,322
Holding current value
$636,658
% of portfolio
0.5%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 17, 2024

BUY
$51.3 - $64.42 $683,418 - $858,203
13,322 New
13,322 $762,000

Others Institutions Holding HALO

About HALOZYME THERAPEUTICS, INC.


  • Ticker HALO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 139,288,992
  • Market Cap $6.66B
  • Description
  • Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...
More about HALO
Track This Portfolio

Track Friedenthal Financial Portfolio

Follow Friedenthal Financial and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Friedenthal Financial, based on Form 13F filings with the SEC.

News

Stay updated on Friedenthal Financial with notifications on news.